Trial Profile
A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs RG 101 (Primary) ; Daclatasvir; Ledipasvir/sofosbuvir; Simeprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Regulus Therapeutics
- 02 Mar 2017 Top-line results published in the Regulus Therapeutics media release.
- 02 Mar 2017 Status changed from active, no longer recruiting to completed, according to Regulus Therapeutics media release.
- 23 Feb 2017 This trial is completed in Hungary (end date: 2017-01-18)